| (Values in U.S. Thousands) | Dec, 2022 | Dec, 2021 | Dec, 2020 | Dec, 2019 | Dec, 2018 |
| Sales | 1,914,300 | 2,208,800 | 2,213,400 | 3,162,500 | 3,215,600 |
| Sales Growth | -13.33% | -0.21% | -30.01% | -1.65% | -0.19% |
| Net Income | -911,200 | -717,400 | -944,600 | -996,500 | -3,607,000 |
| Net Income Growth | -27.01% | +24.05% | +5.21% | +72.37% | -268.99% |
Mallinckrodt Plc (MNK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Mallinckrodt Plc. develops, produces, markets and distributes specialty pharmaceutical products and therapies. The company offers branded pharmaceutical products for autoimmune and rare diseases in specialty areas such as rheumatology, nephrology, neurology, pulmonology and ophthalmology. It also offers immunotherapy, oncology and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. Mallinckrodt Plc. is headquartered in Dublin, Ireland.